Given these data, Kirschner, the director of program development at the Cancer Survivorship and Supportive Care Professionals ...

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Panelists discuss how the unprecedented 5-year progression-free survival benefit (60% vs 8%) demonstrated in the CROWN trial ...

Experienced oncology nurses and APPs can help nurses newer to the field understand who is more at risk of opioid addiction, ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The ...

Explore essential mental health support strategies for older adults with cancer, addressing grief, community resources, and ...

Panelists discuss the importance of effective communication and multidisciplinary collaboration in managing immunotherapy toxicities and ensuring seamless patient care, while highlighting promising ...

Establishing a routine early in treatment helps proactively manage adverse effects associated with CDK4/6 inhibitors, says ...

Panelists discuss the complexities of managing metastatic melanoma with asymptomatic brain metastases in patients with good performance status, emphasizing challenges posed by treatment resistance and ...

A generic version of ibrutinib was granted tentative approval by the FDA for use in CLL and SLL with 17p deletion and ...

Panelists discuss that talquetamab dose modifications are guided primarily by patient symptoms and adverse effects, with ...

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according ...